Prosecution Insights
Last updated: November 20, 2026
Application No. 18/694,771

ANALYTICAL METHOD

Non-Final OA §103
Filed
Mar 22, 2024
Priority
Sep 24, 2021 — JP 2021-155278 +1 more
Examiner
KWAK, DEAN P
Art Unit
1795
Tech Center
1700 — Chemical & Materials Engineering
Assignee
SHIMADZU Corporation
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
400 granted / 678 resolved
-6.0% vs TC avg
Strong +37% interview lift
Without
With
+36.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
71 currently pending
Career history
763
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
35.9%
-4.1% vs TC avg
§102
28.4%
-11.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 678 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-2 is/are rejected under 35 U.S.C. 103 as being unpatentable over Iwata (Shimadzu No. L554A, Quick Estimation of the Freshness and the Level of Putrefaction in Fish Meat Using Nexera™ Dual Injection System, March 2020) in view of Qiu et al. (CN 104237412A, rejection refers to Google Patents machine translated version), and further in view of Champion (HPLC Separation Fundamentals, 02/08/2011). Regarding claim 1, Iwata teaches: Claim 1 An analytical method for performing, in parallel (see P1/Dual Injection System Capable of Two Different Analyses Simultaneously): a first analysis step of introducing a non-derivatized first sample (e.g., untreated sample to injection port 1, P2/Fig. 4) into a first column (e.g., Shim-pack GIST 3μm C18 AQ, P2/Table 2) together with a first mobile phase (e.g., buffered water/acetonitrile mobile phase solutions A/B, Table 2), and analyzing components contained in the first sample (e.g., PDA detection, 260nm, Table 2); and a second analysis step of introducing a derivatized second sample (e.g., OPA/FMOC-derivatized histamine/amino-acid sample delivered through injection port 2, P2/Tables 3-4 & Fig. 4) into a second column (e.g., shim-packed Velox C18, P2/Table 2) together with a second mobile phase (e.g., phosphate-buffer mobile phase solution A and acetonitrile/methanol/water mobile phase solution B, Table 2), and analyzing components contained in the second sample (e.g., fluorescence detection Table 2), using the first column and the second column each constituted by an ODS column (e.g., C18 columns, Table 2), wherein the first sample contains inosinic acid (e.g., IMP, peak 2, Table 1), and in the first analysis step, by separating components contained in the first sample (see e.g., ATP-related compound chromatograms in Fig. 5) using the first column having a length of 100mm (Table 2), a chromatogram (Fig. 5) is obtained in which peaks corresponding to inosinic acid (e.g., peak 2). However, Iwata does not explicitly teach: wherein the first sample contains guanylic acid, and in the first analysis step, by separating components contained in the first sample using the first column having a length of 185 mm or more, a chromatogram is obtained in which peaks corresponding to inosinic acid and guanylic acid are separated with a separation degree of 1.5 or more. Qiu teaches: An analytical method for performing: a first analysis step of introducing a non-derivatized first sample (e.g., nucleotide mixture, P6/Example 1, last 3 paragraphs) into a first column (e.g., Waters Atlantis T3C18 (4.6×250mm, 5μm) P7/¶ 1) together with a first mobile phase (e.g., methanol (phase A) and dipotassium hydrogen phosphate buffer (phase B), P7/¶ 5), and analyzing components contained in the first sample (e.g., diode-array detector, P6-7/Example 1); and wherein the first sample contains inosinic acid and guanylic acid (e.g., IMP/GMP, P4/¶ 3), and in the first analysis step, by separating components contained in the first sample (P7/¶ 3+) using the first column having a length of 185 mm or more (e.g., 250mm, P7/¶ 2-3), a chromatogram is obtained (see Fig. 3 for example) in which peaks corresponding to inosinic acid and guanylic acid are separated (see separated IMP GMP in Fig. 3 for example. It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the parallel arrangement of Iwata with the first sample contains inosinic acid and guanylic acid, and the first column having a length of 185 mm or more ODS column, as taught by Qiu to individually analyze the nucleotides while simultaneously analyze derivatized components in the second column. However, modified Iwata does not explicitly teach: a separation degree of 1.5 or more. Champion teaches: An analytical method for performing: a first analysis step of introducing a first sample into a first column (e.g., ZORBAX SB-C18, P34) together with a first mobile phase (e.g., methanol/water or acetonitrile/water P34), and analyzing components contained in the first sample (see P34 for example); and using the first column constituted by an ODS column (e.g., C18, P34), in the first analysis step, by separating components contained in the first sample using the first column having a length of 185 mm or more (e.g., 250mm P34), a chromatogram is obtained (P34) with a 1.5 baseline resolution criteria P29. It would have been obvious to one of ordinary skill in the art at the time the invention was made to select and adjust the disclosed separation methods to obtain the known baseline resolution of at least 1.5, as taught by Champion, to permit reliable and improved measurements of IMP and GMP. Regarding claim 2, modified Iwata teaches: Claim 2 The analytical method according to claim 1, wherein the first analysis step includes a gradient step of gradually increasing a ratio of an organic solvent in the first mobile phase to be introduced into the first column (e.g., 0% to 12%, Table 2) by changing a mixing ratio between a first solution (e.g., solution A: 100:1 water/acetonitrile) and a second solution (e.g., solution B: 80:20 water/acetonitrile) having a higher organic solvent content (e.g., acetonitrile) ratio than that of the first solution (e.g., solution B acetonitrile content). Claim(s) 3 is/are rejected under 35 U.S.C. 103 as being unpatentable over Iwata (Shimadzu No. L554A, Quick Estimation of the Freshness and the Level of Putrefaction in Fish Meat Using Nexera™ Dual Injection System, March 2020) in view of Qiu et al. (CN 104237412A, rejection refers to Google Patents machine translated version), and in view of Champion (HPLC Separation Fundamentals, 02/08/2011), and further in view of Berry et al. (Fast Separation of Seven Biocides Using an Agilent ZORBAX Rapid Resolution High Definition Eclipse Plus C18 1.8 μm Column, 10/29/2009). Regarding claim 3, modified Iwata teaches: Claim 3 The analytical method according to claim 2, wherein the first analysis step includes introducing only the second solution into the first column after the gradient step (e.g., 100% B for 11.51-18.5 min, Table 2). Although a washing step is inferred and commonly practiced in chromatography analysis, the modified Iwata method does not explicitly teach: wherein the first analysis step includes a washing step of washing an inside of the first column. Berry teaches: wherein a first analysis step includes a washing step of washing an inside of a first column (e.g., Column Wash, Table 2) by introducing only a second solution into the first column (e.g., 100% B, Table 2) after a gradient step (see Table 2 & Fig. 5 for example). It would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify Iwata with the wash step, as taught by Berry, to remove retained material and prepare the column for subsequent analyses. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEAN KWAK whose telephone number is (571)270-7072. The examiner can normally be reached M-TH, 4:30 am - 2:30 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LUAN VAN can be reached at (571) 272-8521. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEAN KWAK/Primary Examiner, Art Unit 1795 DEAN KWAK Primary Examiner Art Unit 1795
Read full office action

Prosecution Timeline

Mar 22, 2024
Application Filed
Nov 03, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766514
DIGITAL MICROFLUIDICS APPARATUSES AND METHODS FOR MANIPULATING AND PROCESSING ENCAPSULATED DROPLETS
3y 6m to grant Granted Oct 20, 2026
Patent 12758963
CONTROL OF CELL CONCENTRATION
4y 11m to grant Granted Oct 13, 2026
Patent 12728415
GRAVITY FLOW MICRO-PHYSIOLOGICAL ARTICLE AND DETERMINING A PHYSIOLOGICAL RESPONSE TO A DRUG
4y 10m to grant Granted Sep 08, 2026
Patent 12722153
MICROFLUIDIC CHIP, TEMPERATURE MEASUREMENT METHOD USING THE SAME, AND ANALYSIS DEVICE USING THE SAME
3y 6m to grant Granted Sep 01, 2026
Patent 12708900
WELLS FOR OPTIMIZED SAMPLE LOADING IN MICROFLUIDIC CHIPS
5y 2m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
96%
With Interview (+36.7%)
3y 10m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 678 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month